GeneQuine Biotherapeutics’ Gene Therapy Program for Treatment of Knee Osteoarthritis Acquired by Flexion Therapeutics [ 14 Dec 2017 ]

Knee osteoarthritis program developed by Hamburg-based gene therapy specialist GeneQuine Biotherapeutics acquired by Flexion Therapeutics for up to $64 million. Program holds potential to provide long-lasting pain relief and disease modification, and pending positive pre-clinical results is anticipated to enter clinical trials in 2019.

More


GeneQuine and Panion Eyeing License Deal for Osteoarthritis Gene Therapy in Horses and Dogs [ 18 May 2017 ]

GeneQuine Biotherapeutics GmbH and Panion Animal Health AB have signed a Letter of Intent to facilitate discussions regarding a potential license for GeneQuine’s gene therapy technology to treat osteoarthritis in horses and dogs.

More


Sponsor Fee Waiver for FY 2017 Granted by FDA [ 03 Apr 2017 ]

FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2017

More


Turkey Grants Patent for GeneQuine’s Lead Products [ 02 Mar 2017 ]

Following Europe and China, the Turkish Patent Office grants the Patent for GeneQuine’s Lead Products.

More


Following Europe, China grants Patent for GeneQuine’s Lead Products [ 25 Jan 2017 ]

Chinese Patent Office grants Patent for GeneQuine’s Lead Products.

More